On April 22, 2026, the Acting Attorney General signed the final order that much of the industry had waited two years for — and it is narrower than most of the coverage suggested. The order moves two categories to Schedule III: marijuana products with FDA approval, and marijuana dispensed under state-licensed medical programs. Everything else, including adult-use marijuana sold under state programs like New Jersey’s, remains Schedule I. The trade press largely collapsed that distinction. The distinction is the entire story.
Start with Section 280E, because that is where the money is. 280E’s deduction prohibition applies to trafficking in Schedule I and II substances; relief follows the schedule. Medical-licensed dispensing activity moves out from under 280E once the order is operative for tax purposes. Adult-use dispensing does not. A New Jersey Class 5 retailer operating adult-use only has the same federal tax posture in July 2026 that it had in 2025 — full 280E exposure, no new deductions, no windfall. Any operator, lender, or investor model that priced 280E relief into adult-use cash flows is modeling a contingency, not a rule.
The genuinely new problem belongs to dual-authority operators. A licensee dispensing under both medical and adult-use authorizations now straddles two federal schedules at one premises. Cost accounting between the two revenue streams stops being bookkeeping hygiene and becomes the line between deductible and non-deductible operating expense. Expect the disputes of the next several years to happen in allocation methodology — shared payroll, shared rent, shared inventory cost — not in tax rates.
The question of whether adult-use follows medical is live right now. A broader rescheduling proceeding opened hearings on June 29, 2026, running through July 15. Whatever emerges will take months to finalize and will draw immediate challenge from both directions. Operators should treat the second half of 2026 as a monitoring obligation, not a planning assumption.
What the April order did not change: there is no federal license, no interstate commerce regime, and no change to banking access — marijuana remains a controlled substance at every schedule, and financial institutions’ exposure analysis is largely unchanged. Federal trademark registration remains closed for the underlying products. State regulators — the NJ CRC, the CA DCC — continue to govern exactly as before. And municipal ordinance language keyed to the federal schedules remains operative until each ordinance is amended, which is a quiet drafting problem now sitting inside hundreds of local codes.
The practical posture: medical-side operators have a real tax-year and estimated-payments question to solve with their CPA now. Adult-use operators have a watching brief on the July hearing record — and a reason to be skeptical of anyone selling them a Schedule III strategy today.